{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"320"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"27"}],"units":"Participants"}],"description":"Phase 1 (Safety Run-In) was conducted in 5 dose cohorts in up to 30 subjects in a standard 3+3 dose-escalation design to establish an MTD and recommended Phase 2 dose (RP2D). Safety assessed through the monitoring of adverse events (AEs), serious adverse events (SAEs), clinical laboratory parameters (hematology and serum chemistry), vital sign measurements, electrocardiograms (ECGs) and physical examinations.","groups":[{"description":"All study participants who received at least 1 dose of E6201 at 240 or 320 mg/m\\^2 IV weekly, or at 160, 240 or 320 mg/m\\^2 IV twice weekly","id":"OG000","title":"All Participants"}],"paramType":"NUMBER","populationDescription":"Full analysis set (FAS): All subjects who were administered any fraction of a dose of study medication","reportingStatus":"POSTED","timeFrame":"Up to 6 weeks for each dose cohort","title":"Maximum Tolerated Dose (MTD) of E6201","type":"PRIMARY","unitOfMeasure":"E6201 MTD (mg/m^2) IV twice weekly"}